• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Enasidenib mesylate

CAS No. 1650550-25-6

Enasidenib mesylate ( —— )

产品货号. M33941 CAS No. 1650550-25-6

Enasidenib mesylate 是一种有效的,可口服的,可逆的,选择性的 IDH2 突变酶抑制剂。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥323 有现货
10MG ¥517 有现货
25MG ¥696 有现货
50MG ¥884 有现货
100MG ¥1125 有现货
500MG ¥2815 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Enasidenib mesylate
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Enasidenib mesylate 是一种有效的,可口服的,可逆的,选择性的 IDH2 突变酶抑制剂。
  • 产品描述
    Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
  • 体外实验
    Enasidenib (AG-221) reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Enasidenib induces differentiation and impairs self-renewal of IDH2-mutant leukemia cells, effects that are further enhanced by simultaneous inhibition of Flt3ITD. Enasidenib (AG-221) therapy induces differentiation of leukemic cells, with an increase in the CD11b+ population and a decrease in the c-Kit+ population in the peripheral blood at 2 wks.
  • 体内实验
    Treatment with enasidenib (AG-221) significantly improves survival in an IDH2-mutant acute myeloid leukemia (AML) primary xenograft mouse model. Enasidenib (AG-221), a mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Enasidenib treatment (10 mg/kg or 100 mg/kg bid) leads to a reduction in 2-HG in vivo (96.7% below pre-treatment levels). Moreover, Enasidenib treatment restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression (mean MEP% mean, 39% Veh vs 50% AG-221). Enasidenib therapy reverses the effects of mutant IDH2; a significant reduction is observed in DNA methylation, including 180 genes that have 20 or more hypomethylated differentially methylated cytosines (DMCs) following treatment. Enasidenib (100 mg/kg bid) treatment of mice engrafted with Mx1-Cre IDH2R140QFlt3ITD AML cells markedly reduces 2-hydroxyglutarate (2-HG) levels consistent with on target inhibition. Enasidenib inhibits mutant IDH2-mediated 2-HG production.
  • 同义词
    ——
  • 通路
    Metabolic Enzyme/Protease
  • 靶点
    Dehydrogenase
  • 受体
    Dehydrogenase
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    1650550-25-6
  • 分子量
    569.48
  • 分子式
    C20H21F6N7O4S
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO 中的溶解度 : ≥ 100 mg/mL (175.60 mM )
  • SMILES
    CS(O)(=O)=O.CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015
产品手册
关联产品
  • CP-642931

    Sorbitol dehydrogenase-IN-1 是一种有效的具有口服活性的山梨醇脱氢酶 sorbitol dehydrogenase 抑制剂,对大鼠和人类的 IC50 s 值分别为 4、5 nM。

  • KS100

    KS100 是一种有效的 ALDH 抑制剂,对 ALDH1A1、ALDH2 和 ALDH3A1 的 IC50 分别为 334、2137、360 nM。KS100 具有低毒性的抗增殖和抗癌作用。KS100 显著增加 ROS 活性、脂质过氧化和有毒醛的积累。KS100 诱导细胞凋亡 (apoptosis) 和细胞周期停滞在 G2/M 期。

  • LDH-IN-1

    LDH-IN-1 是一种新型吡唑类人乳酸脱氢酶 (LDH) 抑制剂,对 LDHA 和 LDHB 的 IC50 值分别为 32 和 27 nM。 LDH-IN-1 抑制 MiaPaCa2 胰腺癌和 A673 肉瘤细胞的生长,IC50 分别为 2.23 和 1.21 μM。